Comparing the immunomodulatory properties of bone marrow, adipose tissue, and birth-associated tissue mesenchymal stromal cells

Frontiers in Immunology

Volumn 6, Issue NOV, 2015, Pages

  Mattar, Philipp ^a,b   Bieback, Karen ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b German Red Cross Blood Donation Service Baden Württemberg Hessen   (Germany)

Author keywords

Adipose tissue; Bone marrow; Immunomodulation; Macrophages; Mesenchymal stromal cells; Regulatory T cells; T cells; Umbilical cord

Indexed keywords

ADIPOSE TISSUE; BONE MARROW; DENDRITIC CELL; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; MACROPHAGE; MESENCHYMAL STROMA CELL; MONOCYTE; PLACENTA; REGENERATIVE MEDICINE; T LYMPHOCYTE SUBPOPULATION; TISSUE ENGINEERING; UMBILICAL CORD BLOOD;

EID: 84949551824     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00560     Document Type: Short Survey

References (90)

1. Sharma RR, Pollock K, Hubel A, McKenna D. Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices. Transfusion (2014) 54(5):1418-37. doi:10.1111/trf.12421.
2. Wang Y, Chen X, Cao W, Shi Y. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol (2014) 15(11):1009-16. doi:10.1038/ni.3002.
3. Friedenstein AJ, Gorskaja JF, Kulagina NN. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol (1976) 4(5):267-74.
4. de Girolamo L, Lucarelli E, Alessandri G, Avanzini MA, Bernardo ME, Biagi E, et al. Mesenchymal stem/stromal cells: a new "cells as drugs" paradigm. Efficacy and critical aspects in cell therapy. Curr Pharm Des (2013) 19(13):2459-73. doi:10.2174/1381612811319130015.
5. Kern S, Eichler H, Stoeve J, Kluter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells (2006) 24(5):1294-301. doi:10.1634/stemcells.2005-0342.
6. Bieback K, Brinkmann I. Mesenchymal stromal cells from human perinatal tissues: from biology to cell therapy. World J Stem Cells (2010) 2(4):81-92. doi:10.4252/wjsc.v2.i4.81.
7. Hass R, Kasper C, Bohm S, Jacobs R. Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal (2011) 9:12. doi:10.1186/1478-811X-9-12.
8. Bieback K, Kern S, Kluter H, Eichler H. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells (2004) 22(4):625-34. doi:10.1634/stemcells.22-4-625.
9. Barlow S, Brooke G, Chatterjee K, Price G, Pelekanos R, Rossetti T, et al. Comparison of human placenta-and bone marrow-derived multipotent mesenchymal stem cells. Stem Cells Dev (2008) 17(6):1095-107. doi:10.1089/scd.2007.0154.
10. In 't Anker PS, Scherjon SA, Kleijburg-van der Keur C, de Groot-Swings GM, Claas FH, Fibbe WE, et al. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells (2004) 22(7):1338-45. doi:10.1634/stemcells.2004-0058.
11. Hoogduijn MJ, Betjes MG, Baan CC. Mesenchymal stromal cells for organ transplantation: different sources and unique characteristics? Curr Opin Organ Transplant (2014) 19(1):41-6. doi:10.1097/MOT.0000000000000036.
12. Xishan Z, Baoxin H, Xinna Z, Jun R. Comparison of the effects of human adipose and bone marrow mesenchymal stem cells on T lymphocytes. Cell Biol Int (2013) 37(1):11-8. doi:10.1002/cbin.10002.
13. Yang ZX, Han ZB, Ji YR, Wang YW, Liang L, Chi Y, et al. CD106 identifies a subpopulation of mesenchymal stem cells with unique immunomodulatory properties. PLoS One (2013) 8(3):e59354. doi:10.1371/journal.pone.0059354.
14. Maumus M, Peyrafitte JA, D'Angelo R, Fournier-Wirth C, Bouloumie A, Casteilla L, et al. Native human adipose stromal cells: localization, morphology and phenotype. Int J Obes (2011) 35(9):1141-53. doi:10.1038/ijo.2010.269.
15. Bourin P, Bunnell BA, Casteilla L, Dominici M, Katz AJ, March KL, et al. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytotherapy (2013) 15(6):641-8. doi:10.1016/j.jcyt.2013.02.006.
16. Karagianni M, Brinkmann I, Kinzebach S, Grassl M, Weiss C, Bugert P, et al. A comparative analysis of the adipogenic potential in human mesenchymal stromal cells from cord blood and other sources. Cytotherapy (2013) 15(1):76-88. doi:10.1016/j.jcyt.2012.11.001.
17. Reinisch A, Etchart N, Thomas D, Hofmann NA, Fruehwirth M, Sinha S, et al. Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation. Blood (2015) 125(2):249-60. doi:10.1182/blood-2014-04-572255.
18. Krampera M, Galipeau J, Shi Y, Tarte K, Sensebe L; MSC Committee of the International Society for Cellular Therapy (ISCT). Immunological characterization of multipotent mesenchymal stromal cells-the International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy (2013) 15(9):1054-61. doi:10.1016/j.jcyt.2013.02.010.
19. Rasmusson I, Ringden O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res (2005) 305(1):33-41. doi:10.1016/j.yexcr.2004.12.013.
20. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood (2006) 108(6):2114-20. doi:10.1182/blood-2005-11-011650.
21. Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol (2014) 32(3):252-60. doi:10.1038/nbt.2816.
22. Prasanna SJ, Gopalakrishnan D, Shankar SR, Vasandan AB. Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow-and Wharton jelly mesenchymal stem cells differentially. PLoS One (2010) 5(2):e9016. doi:10.1371/journal.pone.0009016.
23. Duffy MM, Ritter T, Ceredig R, Griffin MD. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther (2011) 2(4):34. doi:10.1186/scrt75.
24. Tsai MS, Hwang SM, Chen KD, Lee YS, Hsu LW, Chang YJ, et al. Functional network analysis of the transcriptomes of mesenchymal stem cells derived from amniotic fluid, amniotic membrane, cord blood, and bone marrow. Stem Cells (2007) 25(10):2511-23. doi:10.1634/stemcells.2007-0023.
25. Baglio SR, Rooijers K, Koppers-Lalic D, Verweij FJ, Perez Lanzon M, Zini N, et al. Human bone marrow-and adipose-mesenchymal stem cells secrete exosomes enriched in distinctive miRNA and tRNA species. Stem Cell Res Ther (2015) 6(1):127. doi:10.1186/s13287-015-0116-z.
26. Barcia RN, Santos JM, Filipe M, Teixeira M, Martins JP, Almeida J, et al. What makes umbilical cord tissue-derived mesenchymal Stromal cells superior immunomodulators when compared to bone marrow derived mesenchymal stromal cells? Stem Cells Int (2015) 2015:583984. doi:10.1155/2015/583984.
27. Castro-Manrreza ME, Mayani H, Monroy-Garcia A, Flores-Figueroa E, Chavez-Rueda K, Legorreta-Haquet V, et al. Human mesenchymal stromal cells from adult and neonatal sources: a comparative in vitro analysis of their immunosuppressive properties against T cells. Stem Cells Dev (2014) 23(11):1217-32. doi:10.1089/scd.2013.0363.
28. Ivanova-Todorova E, Bochev I, Mourdjeva M, Dimitrov R, Bukarev D, Kyurkchiev S, et al. Adipose tissue-derived mesenchymal stem cells are more potent suppressors of dendritic cells differentiation compared to bone marrow-derived mesenchymal stem cells. Immunol Lett (2009) 126(1-2):37-42. doi:10.1016/j.imlet.2009.07.010.
29. Jin HJ, Bae YK, Kim M, Kwon SJ, Jeon HB, Choi SJ, et al. Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy. Int J Mol Sci (2013) 14(9):17986-8001. doi:10.3390/ijms140917986.
30. Li X, Bai J, Ji X, Li R, Xuan Y, Wang Y. Comprehensive characterization of four different populations of human mesenchymal stem cells as regards their immune properties, proliferation and differentiation. Int J Mol Med (2014) 34(3):695-704. doi:10.3892/ijmm.2014.1821.
31. Luan X, Li G, Wang G, Wang F, Lin Y. Human placenta-derived mesenchymal stem cells suppress T cell proliferation and support the culture expansion of cord blood CD34(+) cells: a comparison with human bone marrow-derived mesenchymal stem cells. Tissue Cell (2013) 45(1):32-8. doi:10.1016/j.tice.2012.09.002.
32. Montespan F, Deschaseaux F, Sensebe L, Carosella ED, Rouas-Freiss N. Osteodifferentiated mesenchymal stem cells from bone marrow and adipose tissue express HLA-G and display immunomodulatory properties in HLA-mismatched settings: implications in bone repair therapy. J Immunol Res (2014) 2014:230346. doi:10.1155/2014/230346.
33. Najar M, Raicevic G, Boufker HI, Fayyad Kazan H, De Bruyn C, Meuleman N, et al. Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: combined comparison of adipose tissue, Wharton's jelly and bone marrow sources. Cell Immunol (2010) 264(2):171-9. doi:10.1016/j.cellimm.2010.06.006.
34. Najar M, Raicevic G, Fayyad-Kazan H, De Bruyn C, Bron D, Toungouz M, et al. Impact of different mesenchymal stromal cell types on T-cell activation, proliferation and migration. Int Immunopharmacol (2013) 15(4):693-702. doi:10.1016/j.intimp.2013.02.020.
35. Puissant B, Barreau C, Bourin P, Clavel C, Corre J, Bousquet C, et al. Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br J Haematol (2005) 129(1):118-29. doi:10.1111/j.1365-2141.2005.05409.x.
36. Ribeiro A, Laranjeira P, Mendes S, Velada I, Leite C, Andrade P, et al. Mesenchymal stem cells from umbilical cord matrix, adipose tissue and bone marrow exhibit different capability to suppress peripheral blood B, natural killer and T cells. Stem Cell Res Ther (2013) 4(5):125. doi:10.1186/scrt336.
37. Roemeling-van Rhijn M, Khairoun M, Korevaar SS, Lievers E, Leuning DG, Ijzermans JN, et al. Human bone marrow and adipose tissue-derived mesenchymal stromal cells are immunosuppressive and in a humanized allograft rejection model. J Stem Cell Res Ther (2013) 6(Suppl 1):20780. doi:10.4172/2157-7633.S6-001.
38. Roemeling-van Rhijn M, Reinders ME, Franquesa M, Engela AU, Korevaar SS, Roelofs H, et al. Human allogeneic bone marrow and adipose tissue derived mesenchymal stromal cells induce CD8+ cytotoxic T cell reactivity. J Stem Cell Res Ther (2013) 3(Suppl 6):004. doi:10.4172/2157-7633.S6-004.
39. StubbendorffM, Deuse T, Hua X, Phan TT, Bieback K, Atkinson K, et al. Immunological properties of extraembryonic human mesenchymal stromal cells derived from gestational tissue. Stem Cells Dev (2013) 22(19):2619-29. doi:10.1089/scd.2013.0043.
40. Yoo KH, Jang IK, Lee MW, Kim HE, Yang MS, Eom Y, et al. Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues. Cell Immunol (2009) 259(2):150-6. doi:10.1016/j.cellimm.2009.06.010.
41. Larocca RA, Moraes-Vieira PM, Bassi EJ, Semedo P, de Almeida DC, da Silva MB, et al. Adipose tissue-derived mesenchymal stem cells increase skin allograft survival and inhibit Th-17 immune response. PLoS One (2013) 8(10):e76396. doi:10.1371/journal.pone.0076396.
42. Jacobs SA, Roobrouck VD, Verfaillie CM, Van Gool SW. Immunological characteristics of human mesenchymal stem cells and multipotent adult progenitor cells. Immunol Cell Biol (2013) 91(1):32-9. doi:10.1038/icb.2012.64.
43. Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood (2005) 105(7):2821-7. doi:10.1182/blood-2004-09-3696.
44. Fierabracci A, Del Fattore A, Luciano R, Muraca M, Teti A, Muraca M. Recent advances in mesenchymal stem cell immunomodulation: the role of microvesicles. Cell Transplant (2015) 24(2):133-49. doi:10.3727/096368913X675728.
45. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood (2002) 99(10):3838-43. doi:10.1182/blood. V99.10.3838.
46. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood (2004) 103(12):4619-21. doi:10.1182/blood-2003-11-3909.
47. Wang Q, Yang Q, Wang Z, Tong H, Ma L, Zhang Y, et al. Comparative analysis of human mesenchymal stem cells from fetal-bone marrow, adipose tissue, and Warton's jelly as sources of cell immunomodulatory therapy. Hum Vaccin Immunother (2015). doi:10.1080/21645515.2015.1030549.
48. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood (2005) 105(4):1815-22. doi:10.1182/blood-2004-04-1559.
49. Carrion F, Nova E, Luz P, Apablaza F, Figueroa F. Opposing effect of mesenchymal stem cells on Th1 and Th17 cell polarization according to the state of CD4+ T cell activation. Immunol Lett (2011) 135(1-2):10-6. doi:10.1016/j.imlet.2010.09.006.
50. Sun L, Akiyama K, Zhang H, Yamaza T, Hou Y, Zhao S, et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells (2009) 27(6):1421-32. doi:10.1002/stem.68.
51. Cho KS, Kim YW, Kang MJ, Park HY, Hong SL, Roh HJ. Immunomodulatory effect of mesenchymal stem cells on T lymphocyte and cytokine expression in nasal polyps. Otolaryngol Head Neck Surg (2014) 150(6):1062-70. doi:10.1177/0194599814525751.
52. Kang B-J, Ryu H-H, Park SS, Koyama Y, Kikuchi M, Woo H-M, et al. Comparing the osteogenic potential of canine mesenchymal stem cells derived from adipose tissues, bone marrow, umbilical cord blood, and Wharton's jelly for treating bone defects. J Vet Sci (2012) 13(3):299. doi:10.4142/jvs.2012.13.3.299.
53. English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, Mahon BP. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol (2009) 156(1):149-60. doi:10.1111/j.1365-2249.2009.03874.x.
54. Engela AU, Baan CC, Dor FJ, Weimar W, Hoogduijn MJ. On the interactions between mesenchymal stem cells and regulatory T cells for immunomodulation in transplantation. Front Immunol (2012) 3:126. doi:10.3389/fimmu.2012.00126.
55. Selleri S, Dieng MM, Nicoletti S, Louis I, Beausejour C, Le Deist F, et al. Cord-blood-derived mesenchymal stromal cells downmodulate CD4+ T-cell activation by inducing IL-10-producing Th1 cells. Stem Cells Dev (2013) 22(7):1063-75. doi:10.1089/scd.2012.0315.
56. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell (2000) 100(6):655-69. doi:10.1016/S0092-8674(00)80702-3.
57. Batten P, Sarathchandra P, Antoniw JW, Tay SS, Lowdell MW, Taylor PM, et al. Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: relevance to tissue engineering human heart valves. Tissue Eng (2006) 12(8):2263-73. doi:10.1089/ten.2006.12.2263.
58. Algeri M, Conforti A, Pitisci A, Starc N, Tomao L, Bernardo ME, et al. Mesenchymal stromal cells and chronic inflammatory bowel disease. Immunol Lett (2015). doi:10.1016/j.imlet.2015.06.018.
59. Singh RP, Hasan S, Sharma S, Nagra S, Yamaguchi DT, Wong DT, et al. Th17 cells in inflammation and autoimmunity. Autoimmun Rev (2014) 13(12):1174-81. doi:10.1016/j.autrev.2014.08.019.
60. Lee JJ, Jeong HJ, Kim MK, Wee WR, Lee WW, Kim SU, et al. CD39-mediated effect of human bone marrow-derived mesenchymal stem cells on the human Th17 cell function. Purinergic Signal (2014) 10(2):357-65. doi:10.1007/s11302-013-9385-0.
61. Tatara R, Ozaki K, Kikuchi Y, Hatanaka K, Oh I, Meguro A, et al. Mesenchymal stromal cells inhibit Th17 but not regulatory T-cell differentiation. Cytotherapy (2011) 13(6):686-94. doi:10.3109/14653249.2010.542456.
62. Qu X, Liu X, Cheng K, Yang R, Zhao RC. Mesenchymal stem cells inhibit Th17 cell differentiation by IL-10 secretion. Exp Hematol (2012) 40(9):761-70. doi:10.1016/j.exphem.2012.05.006.
63. Eljaafari A, Tartelin ML, Aissaoui H, Chevrel G, Osta B, Lavocat F, et al. Bone marrow-derived and synovium-derived mesenchymal cells promote Th17 cell expansion and activation through caspase 1 activation: contribution to the chronicity of rheumatoid arthritis. Arthritis Rheum (2012) 64(7):2147-57. doi:10.1002/art.34391.
64. Li L, Liu S, Xu Y, Zhang A, Jiang J, Tan W, et al. Human umbilical cord-derived mesenchymal stem cells downregulate inflammatory responses by shifting the Treg/Th17 profile in experimental colitis. Pharmacology (2013) 92(5-6):257-64. doi:10.1159/000354883.
65. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol (2012) 30:531-64. doi:10.1146/annurev.immunol.25.022106.141623.
66. Chattopadhyay G, Shevach EM. Antigen-specific induced T regulatory cells impair dendritic cell function via an IL-10/MARCH1-dependent mechanism. J Immunol (2013) 191(12):5875-84. doi:10.4049/jimmunol.1301693.
67. Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol (2010) 11(1):7-13. doi:10.1038/ni.1818.
68. Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L, et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells (2008) 26(1):212-22. doi:10.1634/stemcells.2007-0554.
69. Melief SM, Schrama E, Brugman MH, Tiemessen MM, Hoogduijn MJ, Fibbe WE, et al. Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. Stem Cells (2013) 31(9):1980-91. doi:10.1002/stem.1432.
70. Nemeth K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med (2009) 15(1):42-9. doi:10.1038/nm.1905.
71. Zhang W, Ge W, Li C, You S, Liao L, Han Q, et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev (2004) 13(3):263-71. doi:10.1089/154732804323099190.
72. Maccario R, Podesta M, Moretta A, Cometa A, Comoli P, Montagna D, et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica (2005) 90(4):516-25.
73. Wang L, Zhao Y, Shi S. Interplay between mesenchymal stem cells and lymphocytes: implications for immunotherapy and tissue regeneration. J Dent Res (2012) 91(11):1003-10. doi:10.1177/0022034512460404.
74. Casiraghi F, Azzollini N, Cassis P, Imberti B, Morigi M, Cugini D, et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol (2008) 181(6):3933-46. doi:10.4049/jimmunol.181.6.3933.
75. Fan XB, Gay FPH, Ong SY, Ang JML, Chu PPY, Bari S, et al. Mesenchymal stromal cell supported umbilical cord blood ex vivo expansion enhances regulatory T cells and reduces graft versus host disease. Cytotherapy (2013) 15(5):610-9. doi:10.1016/j.jcyt.2012.12.007.
76. Tasso R, Ilengo C, Quarto R, Cancedda R, Caspi RR, Pennesi G. Mesenchymal stem cells induce functionally active T-regulatory lymphocytes in a paracrine fashion and ameliorate experimental autoimmune uveitis. Invest Ophthalmol Vis Sci (2012) 53(2):786-93. doi:10.1167/iovs.11-8211.
77. Chao YH, Wu HP, Wu KH, Tsai YG, Peng CT, Lin KC, et al. An increase in CD3+CD4+CD25+ regulatory T cells after administration of umbilical cord-derived mesenchymal stem cells during sepsis. PLoS One (2014) 9(10):e110338. doi:10.1371/journal.pone.0110338.
78. Hof-Nahor I, Leshansky L, Shivtiel S, Eldor L, Aberdam D, Itskovitz-Eldor J, et al. Human mesenchymal stem cells shift CD8+ T cells towards a suppressive phenotype by inducing tolerogenic monocytes. J Cell Sci (2012) 125(Pt 19):4640-50. doi:10.1242/jcs.108860.
79. Chen PM, Liu KJ, Hsu PJ, Wei CF, Bai CH, Ho LJ, et al. Induction of immunomodulatory monocytes by human mesenchymal stem cell-derived hepatocyte growth factor through ERK1/2. J Leukoc Biol (2014) 96(2):295-303. doi:10.1189/jlb.3A0513-242R.
80. Laranjeira P, Gomes J, Pedreiro S, Pedrosa M, Martinho A, Antunes B, et al. Human bone marrow-derived mesenchymal stromal cells differentially inhibit cytokine production by peripheral blood monocytes subpopulations and myeloid dendritic cells. Stem Cells Int (2015) 2015:819084. doi:10.1155/2015/819084.
81. Saeidi M, Masoud A, Shakiba Y, Hadjati J, Mohyeddin Bonab M, Nicknam MH, et al. Immunomodulatory effects of human umbilical cord Wharton's jelly-derived mesenchymal stem cells on differentiation, maturation and endocytosis of monocyte-derived dendritic cells. Iran J Allergy Asthma Immunol (2013) 12(1):37-49.
82. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood (2005) 105(10):4120-6. doi:10.1182/blood-2004-02-0586.
83. Du Rocher B, Mencalha AL, Gomes BE, Abdelhay E. Mesenchymal stromal cells impair the differentiation of CD14(++) CD16(-) CD64(+) classical monocytes into CD14(++) CD16(+) CD64(++) activate monocytes. Cytotherapy (2012) 14(1):12-25. doi:10.3109/14653249.2011.594792.
84. Kim N, Cho SG. New strategies for overcoming limitations of mesenchymal stem cell-based immune modulation. Int J Stem Cells (2015) 8(1):54-68. doi:10.15283/ijsc.2015.8.1.54.
85. Galderisi U, Giordano A. The gap between the physiological and therapeutic roles of mesenchymal stem cells. Med Res Rev (2014) 34(5):1100-26. doi:10.1002/med.21322.
86. Shi C. Recent progress toward understanding the physiological function of bone marrow mesenchymal stem cells. Immunology (2012) 136(2):133-8. doi:10.1111/j.1365-2567.2012.03567.x.
87. Kronsteiner B, Wolbank S, Peterbauer A, Hackl C, Redl H, van Griensven M, et al. Human mesenchymal stem cells from adipose tissue and amnion influence T-cells depending on stimulation method and presence of other immune cells. Stem Cells Dev (2011) 20(12):2115-26. doi:10.1089/scd.2011.0031.
88. Najar M, Rouas R, Raicevic G, Boufker HI, Lewalle P, Meuleman N, et al. Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy (2009) 11(5):570-83. doi:10.1080/14653240903079377.
89. Menard C, Pacelli L, Bassi G, Dulong J, Bifari F, Bezier I, et al. Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls. Stem Cells Dev (2013) 22(12):1789-801. doi:10.1089/scd.2012.0594.
90. Copland IB, Garcia MA, Waller EK, Roback JD, Galipeau J. The effect of platelet lysate fibrinogen on the functionality of MSCs in immunotherapy. Biomaterials (2013) 34(32):7840-50. doi:10.1016/j.biomaterials.2013.06.050.